• Preserving Phosphorylation: Strategic Advances with Phosphat

  2026-05-20

  This article examines the mechanistic necessity and translational impact of robust phosphatase inhibition in phosphoprotein research, contextualized by new insights into autophagic flux and hepatic steatosis. It offers actionable guidance for optimizing protein phosphorylation preservation, highlights the capabilities of APExBIO's Phosphatase Inhibitor Cocktail 3, and provides a forward-looking perspective for researchers seeking reproducible, clinically relevant signaling data.

• LL-37 and Mimetics: Selective Antibiofilm Activity via Cryst

  2026-05-19

  This study investigates the antimicrobial and antibiofilm properties of the human peptide LL-37 and two truncated mimetics, KE-18 and KR-12, against major pathogens. It highlights the use of crystal violet staining to distinguish between biocidal and biofilm-preventive effects, offering insights for therapeutic development and assay design.

• Berberine Hydrochloride: Mechanistic Leverage in Translation

  2026-05-19

  This thought-leadership article explores the emerging translational landscape of Berberine hydrochloride, focusing on its role in gut-bone axis modulation, metabolic regulation, and osteoimmune homeostasis. Integrating recent mechanistic advances—including tuft cell expansion and AMPK activation—the discussion offers experimental parameters, strategic guidance, and a forward-looking perspective for researchers pursuing type 2 diabetes and osteoporosis models. The piece contextualizes APExBIO's Berberine hydrochloride within cutting-edge preclinical workflows and differentiates itself by bridging metabolic and osteoimmune domains, escalating the discourse beyond standard product summaries.

• OSMI-1: Applied O-GlcNAc Transferase Inhibitor in Placental

  2026-05-18

  OSMI-1 enables precision modulation of O-GlcNAcylation in cellular and placental research, directly supporting advanced workflows in ferroptosis and trophoblast function studies. Its robust inhibition profile, validated in both in vitro and in vivo models, makes it a go-to tool for dissecting O-GlcNAc-mediated mechanisms and troubleshooting complex protein modification assays.

• Propranolol: Applied Workflows for β-Adrenergic Blockade Res

  2026-05-18

  Propranolol stands out as a non-selective β-adrenergic receptor blocker offering translational value in cardiovascular, metabolic, and neurobiological research. This article delivers actionable workflows, troubleshooting strategies, and evidence-backed parameters for leveraging propranolol in both cellular and in vivo models.

• Bestatin Hydrochloride: Applied Workflows for Tumor & Angiog

  2026-05-17

  Bestatin hydrochloride (Ubenimex) is a dual aminopeptidase N/B inhibitor that empowers advanced studies in angiogenesis inhibition and tumor biology. This article delivers protocol-enhancing workflows, troubleshooting strategies, and translational insights—bridging foundational neuroscience and cancer research with practical, evidence-based guidance.

• Mapping Metabolite Regulation of TET2 via Biochemical and ST

  2026-05-16

  This protocol paper introduces a combined biochemical and STD NMR workflow for dissecting metabolite binding and regulatory effects on human TET2 dioxygenase. By validating both activating and inhibitory metabolites, the study offers a framework to explore the metabolic-epigenetic interface, with important implications for cancer and metabolic disease research.

• 5-hme-dCTP: Precision Epigenetic Mapping & Context-Dependent

  2026-05-15

  Explore how 5-hme-dCTP (5-Hydroxymethyl-2’-deoxycytidine-5’-Triphosphate) redefines DNA hydroxymethylation assays with genomic context-aware insights. This guide uniquely analyzes recent breakthroughs in plant epigenetics to optimize your research decisions.

• SB743921: Redefining KSP Inhibition with Quantitative Drug R

  2026-05-15

  Explore how SB743921, a potent kinesin spindle protein inhibitor, enables high-resolution cell cycle arrest assays and quantitative drug response evaluation for advanced cancer research. This article uniquely bridges molecular mechanism with assay design, offering actionable insights beyond protocol guides.

• Applied Workflows with JNJ-26854165 (Serdemetan) in Cancer R

  2026-05-14

  JNJ-26854165 (Serdemetan) from APExBIO enables precise p53 pathway modulation, delivering robust anti-proliferative, apoptosis, and radiosensitization effects in p53 wild-type tumor models. This article translates advanced in vitro workflow design and troubleshooting into actionable protocols for reliable cancer research outcomes.

• Mac-1 Deficiency Reduces Cardiac Remodeling via Macrophage M

  2026-05-14

  This study reveals that Mac-1 deficiency significantly mitigates pathological cardiac remodeling and dysfunction caused by pressure overload in mice, primarily by suppressing macrophage infiltration and M1 polarization. These findings highlight Mac-1 as a promising therapeutic target for heart failure and emphasize the importance of immune regulation in cardiac pathology.

• Z-WEHD-FMK: Strategic Caspase Inhibition in Translational Re

  2026-05-13

  This thought-leadership article examines Z-WEHD-FMK (Z-Trp-Glu(OMe)-His-Asp(OMe)-FMK) as a precision tool for dissecting caspase-driven inflammation and pyroptosis. Integrating mechanistic insight from recent cancer research and practical guidance, it offers translational researchers actionable strategies for leveraging irreversible caspase inhibition to unlock new biological and therapeutic understanding.

• Cell Lineage and Thioguanine Sensitivity in Relapsed Childho

  2026-05-13

  This study systematically compared in vitro drug resistance profiles between T-cell and B-cell precursor acute lymphoblastic leukemia (ALL) at relapse in children, focusing on 20 chemotherapeutic agents. A key finding is that relapsed T-cell ALL exhibits increased sensitivity to thiopurine compounds, including thioguanine, suggesting potential for more tailored thiopurine-based interventions.

• 10058-F4: Optimizing c-Myc-Max Dimerization Inhibition Workf

  2026-05-12

  10058-F4 stands apart as a precise c-Myc-Max dimerization inhibitor, enabling targeted disruption of oncogenic transcriptional programs in leukemia and prostate cancer models. This guide delivers actionable workflows, protocol enhancements, and troubleshooting strategies—anchored in the latest bench research—to maximize assay reliability and reproducibility.

• GDH1 Protects Against Congenital Obstructive Nephropathy in

  2026-05-12

  This reference study elucidates the protective role of glutamate dehydrogenase 1 (GDH1) in congenital obstructive nephropathy (CON) using neonatal rat models and in vitro renal epithelial cell systems. The findings establish GDH1 as a modulator of renal fibrosis and apoptosis, with translational implications for veterinary approaches to chronic kidney disease.

3607 records 13/241 page Previous Next First page 上5页 1112131415 下5页 Last page